Serial #98343323
LIVE

Serial Number

98343323

Owner

Tevogen Bio Inc.

Attorney

Anna Kurian Shaw

Filing Date

Jan 5, 2024

Add to watchlist:

No watchlists yet
View on USPTO

Serial #98343323 Trademark

Serial Number: 98343323

Serial #98343323 is a trademark filed by Tevogen Bio Inc. on January 5, 2024. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Tevogen Bio Inc. (6 trademarks)

48 Bridge Street
Metuchen, NJ 08840

Entity Type: 03

Trademark Details

Filing Date

January 5, 2024

Registration Date

Not Registered

Goods & Services

Promoting collaboration in the field of biotechnology to achieve innovation through increased usage of artificial intelligence (AI) technology; promoting the benefits of the use of artificial intelligence (AI) technology in the field of biotechnology to expedite drug development, optimize laboratory processes, unravel complex biological data, and improve patient outcomes; promotion and advocacy services, namely promoting the benefits of the advancement of biomedical, biotechnological, and immunological research and the curing of various diseases utilizing artificial intelligence (AI) technology, by means of public advocacy; promotion and advocacy services, namely, promoting the benefits of increasing the affordability of and increased access to medical services and the treatment of various diseases, as well as overall patient-centric medical services, utilizing artificial intelligence (AI) technology, by means of public advocacy; promotion and advocacy services, namely promoting the benefit of the treatment of various diseases using T cell therapies and artificial intelligence (AI) technology, by means of public advocacy; promoting collaboration within the scientific, research and medical provider communities to achieve advances in the fields of biotechnology, biomedicine, immunology, immunotherapies, and T-cell therapies utilizing artificial intelligence (AI) technology; business operations consulting in the fields of biotechnology and life sciences; business operations consulting in the fields of biotechnology and life sciences to increase business processes automation and increase the efficiency of business operations procedures; database management in the fields of biotechnology and life sciences; creation being compilation and systemization of information into databases and management of databases in the fields of biotechnology and life sciences; compilation of information into computer databases in the fields of biotechnology and life sciences; systematization of data through a medical device network for medical research purposes; business data analysis in the fields of biotechnology and life sciences; business consulting and management in the field of clinical trials, namely, management and compilation of computerized databases in the field of clinical trials for business purposes; business feasibility study planning, namely, for clinical trials; business study data interpretation, namely, for clinical trials; business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval

Providing a website featuring news and information concerning biotechnology, biomedicine, immunology, immunotherapies, and T-cell therapies that utilize artificial intelligence (AI) technology; providing news and information concerning the prevention and treatment of oncological diseases, autoimmune diseases, neurological diseases, viral infections, and COVID-19 using artificial intelligence (AI) enabled technology; providing information concerning use of T cells and other lymphocytes for the prevention and treatment of various diseases, as enhanced by artificial intelligence (AI) technology

Providing a website featuring news and information concerning biomedical, biotechnological, and immunological research that utilizes artificial intelligence (AI) technology; providing news and information concerning biomedical, biotechnological, and immunological research that utilizes artificial intelligence (AI) technology; providing information concerning biomedical research into the efficacy of T cells and other lymphocytes for the prevention and treatment of various diseases, as enhanced by artificial intelligence (AI) technology; providing medical and scientific research information in the fields of T cell therapies, biologics, pharmaceuticals, and clinical trials that utilize artificial intelligence (AI) technology; providing a website featuring temporary access to non-downloadable computer software for expediting drug development, optimizing laboratory processes, and unravelling complex biological data; providing a website featuring temporary access to non-downloadable computer software for human leukocyte antigen (HLA) specificity mapping; providing a website featuring temporary access to non-downloadable computer software for protein sequencing and genome matching; hosting of non-downloadable computer software for clinical trial and patient information database management; providing online, non-downloadable computer software for machine learning and training of artificial intelligence models in the fields of biomedical, biotechnological, and immunological research; analysis of data from databases in the fields of biotechnology and life sciences; collection of data through a medical device network for medical research purposes; providing an internet-based database for business purposes designed to facilitate complex statistical techniques, programming technologies and validation procedures to support clinical trials containing clinical trial data

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 13, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 13, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 13, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 13, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 13, 2025 COAR
WITHDRAWN FROM PUB - OG REVIEW QUERY
Oct 22, 2024 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 1, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 1, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 1, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 1, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 1, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 10, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 9, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 9, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 6, 2024 GNRN
NON-FINAL ACTION E-MAILED
Aug 6, 2024 GNRT
NON-FINAL ACTION WRITTEN
Aug 6, 2024 CNRT
ASSIGNED TO EXAMINER
Aug 1, 2024 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Apr 23, 2024 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 23, 2024 NWOS
NEW APPLICATION ENTERED
Jan 5, 2024 NWAP